U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07055724) titled 'Study of Eque-cel CAR-T Therapy in Newly Diagnosed Severe AL Amyloidosis' on June 26.
Brief Summary: The goal of this clinical trial is to learn if Equecabtagene Autoleucel(Eque-cel), a Chimeric Antigen Receptor T-cell (CAR-T) therapy, works to treat severe Light Chain (AL) Amyloidosis in newly diagnosed adults with Mayo Stage IIIb. It will also learn about the safety and effects of Eque-cel. The main questions it aims to answer are:
Does Eque-cel lead to hematologic remission (achieving a very good partial response or better) in AL amyloidosis? How safe is Eque-cel for these patients, and what side effects might occur?
Participan...